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The CONSORT statement is used worldwide 
to improve the reporting of randomised 
controlled trials. Kenneth schulz and 
colleagues describe the latest version, 
CONSORT 2010, which updates the reporting 
guideline based on new methodological 
evidence and accumulating experience
Randomised controlled trials, when appropriately designed, 
conducted, and reported, represent the gold standard in eval‑
uating healthcare interventions. However, randomised trials 
can yield biased results if they lack methodological rigour.1 To 
assess a trial accurately, readers of a published report need 
complete, clear, and transparent information on its method‑
ology and findings. Unfortunately, attempted assessments 
frequently fail because authors of many trial reports neglect 
to provide lucid and complete descriptions of that critical 
information.2‑4
That lack of adequate reporting fuelled the development of 
the original CONSORT (Consolidated Standards of Reporting 
Trials) statement in 19965 and its revision five years later.6‑8 
While those statements improved the reporting quality for 
some randomised controlled trials,9 10 many trial reports still 
remain inadequate.2 Furthermore, new methodological evi‑
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Flow diagram of the progress through the phases of a parallel randomised trial of two groups 
(that is, enrolment, intervention allocation, follow-up, and data analysis)
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dence and additional experience has accumulated since the 
last revision in 2001. Consequently, we organised a C ONSORT 
Group meeting to update the 2001 statement.6‑8 We introduce 
here the result of that process, CONSORT 2010.
intent of consort 2010
The CONSORT 2010 Statement is this paper including the 
25 item checklist in the table and the flow diagram. It pro‑
vides guidance for reporting all randomised controlled trials, 
but focuses on the most common design type—individually 
randomised, two group, parallel trials. Other trial designs, 
such as cluster randomised trials and non‑inferiority tri‑
als, require varying amounts of additional information. 
CO NSORT extensions for these designs,11 12 and other 
CONSORT products, can be found through the CONSORT 
website (www.consort‑statement.org). Along with the 
CONSORT statement, we have updated the explanation and 
elaboration article,13 which explains the inclusion of each 
checklist item, provides methodological background, and 
gives published examples of transparent reporting.
Diligent adherence by authors to the checklist items facili‑
tates clarity, completeness, and transparency of reporting. 
Explicit descriptions, not ambiguity or omission, best serve 
the interests of all readers. Note that the CONSORT 2010 
Statement does not include recommendations for design‑
ing, conducting, and analysing trials. It solely addresses the 
reporting of what was done and what was found.
Nevertheless, CONSORT does indirectly affect design 
and conduct. Transparent reporting reveals deficiencies in 
research if they exist. Thus, investigators who conduct inad‑
equate trials, but who must transparently report, should 
not be able to pass through the publication process without 
revelation of their trial’s inadequacies. That emerging reality 
should provide impetus to improved trial design and conduct 
in the future, a secondary indirect goal of our work. Moreover, 
CONSORT can help researchers in designing their trial.
Background to consort
Efforts to improve the reporting of randomised control‑
led t rials accelerated in the mid‑1990s, spurred partly by 
methodological research. Researchers had shown for many 
years that authors reported such trials poorly, and empiri‑
cal evidence began to accumulate that some poorly con‑
ducted or poorly reported aspects of trials were associated 
with bias.14 Two initiatives aimed at developing reporting 
guidelines culminated in one of us (DM) and Drummond 
Rennie organising the first CONSORT statement in 1996.5 
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consort 2010 checklist of information to include when reporting a randomised trial*
Section/Topic Item No Checklist item
Title and abstract
1a Identification as a randomised trial in the title
1b Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts21 31)
Introduction
Background and 
objectives
2a Scientific background and explanation of rationale
2b Specific objectives or hypotheses
Methods
Trial design 3a Description of trial design (such as parallel, factorial) including allocation ratio
3b Important changes to methods after trial commencement (such as eligibility criteria), with reasons
Participants 4a Eligibility criteria for participants
4b Settings and locations where the data were collected
Interventions 5 The interventions for each group with sufficient details to allow replication, including how and when they were actually administered
Outcomes 6a Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed
6b Any changes to trial outcomes after the trial commenced, with reasons
Sample size 7a How sample size was determined
7b When applicable, explanation of any interim analyses and stopping guidelines
Randomisation:
 Sequence 
generation
8a Method used to generate the random allocation sequence
8b Type of randomisation; details of any restriction (such as blocking and block size)
 Allocation 
concealment 
mechanism
9 Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the 
sequence until interventions were assigned
Implementation 10 Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions
Blinding 11a If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how
11b If relevant, description of the similarity of interventions
Statistical methods 12a Statistical methods used to compare groups for primary and secondary outcomes
12b Methods for additional analyses, such as subgroup analyses and adjusted analyses
Results
Participant flow (a 
diagram is strongly 
recommended)
13a For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome
13b For each group, losses and exclusions after randomisation, together with reasons
Recruitment 14a Dates defining the periods of recruitment and follow-up
14b Why the trial ended or was stopped
Baseline data 15 A table showing baseline demographic and clinical characteristics for each group
Numbers analysed 16 For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups
Outcomes and 
estimation
17a For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)
17b For binary outcomes, presentation of both absolute and relative effect sizes is recommended
Ancillary analyses 18 Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory
Harms 19 All important harms or unintended effects in each group (for specific guidance see CONSORT for harms28)
Discussion
Limitations 20 Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses
Generalisability 21 Generalisability (external validity, applicability) of the trial findings
Interpretation 22 Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence
Other information
Registration 23 Registration number and name of trial registry
Protocol 24 Where the full trial protocol can be accessed, if available
Funding 25 Sources of funding and other support (such as supply of drugs), role of funders
*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration13 for important clarifications on all the items. If relevant, we also 
recommend reading CONSORT extensions for cluster randomised trials,11 non-inferiority and equivalence trials,12 non-pharmacological treatments,32 herbal interventions,33 and pragmatic 
trials.34 Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see www.consort-statement.org.
Further methodologi cal research on similar topics rein‑
forced earlier findings15 and fed into the revision of 2001.6‑8 
Subsequently, the expanding body of methodological 
research informed the refinement of CONSORT 2010. More 
than 700 studies comprise the CONSORT database (located 
on the CONSORT website), which provides the empirical 
evidence to underpin the CONSORT initiative.
Indeed, CONSORT Group members continually monitor the 
literature. Information gleaned from these efforts provides an 
evidence base on which to update the CONSORT statement. 
We add, drop, or modify items based on that evidence and 
the recommendations of the CONSORT Group, an interna‑
tional and eclectic group of clinical trialists, statisticians, 
epidemiologists, and biomedical editors. The CONSORT 
Executive (KFS, DGA, DM) strives for a balance of established 
and emerging researchers. The membership of the group 
is dynamic. As our work expands in response to emerging 
projects and needed expertise, we invite new members to 
contribute. As such, CONSORT continually assimilates new 
ideas and perspectives. That process informs the continually 
evolving CONSORT statement.
Over time, CONSORT has garnered much support. More 
than 400 journals, published around the world and in 
many languages, have explicitly supported the CONSORT 
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Box 1 | Noteworthy general changes in CONSORT 2010 Statement
We simplified and clarified the wording, such as in items 1, 8, 10, 13, 15, 16, 18, 19, and 21•	
We improved consistency of style across the items by removing the imperative verbs that •	
were in the 2001 version
We enhanced specificity of appraisal by breaking some items into sub-items. Many journals •	
expect authors to complete a CONSORT checklist indicating where in the manuscript the 
items have been addressed. Experience with the checklist noted pragmatic difficulties 
when an item comprised multiple elements. For example, item 4 addresses eligibility of 
participants and the settings and locations of data collection. With the 2001 version, an 
author could provide a page number for that item on the checklist, but might have reported 
only eligibility in the paper, for example, and not reported the settings and locations. 
CONSORT 2010 relieves obfuscations and forces authors to provide page numbers in the 
checklist for both eligibility and settings
 statement. Many other healthcare journals support it with‑
out our knowledge. Moreover, thousands more have implic‑
itly supported it with the endorsement of the CONSORT 
 statement by the International Committee of Medical Journal 
Editors (www.icmje.org). Other prominent editorial groups, 
the Council of Science Editors and the World Association 
of Medical Editors, officially support CONSORT. That sup‑
port seems warranted: when used by authors and journals, 
C ONSORT seems to improve reporting.9
development of consort 2010
Thirty one members of the CONSORT 2010 Group met in 
Montebello, Canada, in January 2007 to update the 2001 
CONSORT statement. In addition to the accumulating evi‑
dence relating to existing checklist items, several new issues 
had come to prominence since 2001. Some participants were 
given primary responsibility for aggregating and synthesis‑
ing the relevant evidence on a particular checklist item of 
interest. Based on that evidence, the group deliberated the 
value of each item. As in prior CONSORT versions, we kept 
only those items deemed absolutely fundamental to report‑
ing a randomised controlled trial. Moreover, an item may be 
fundamental to a trial but not included, such as approval 
by an institutional ethical review board, because funding 
bodies strictly enforce ethical review and medical journals 
usually address reporting ethical review in their instructions 
for authors. Other items may seem desirable, such as report‑
ing on whether on‑site monitoring was done, but a lack of 
empirical evidence or any consensus on their value cautions 
against inclusion at this point. The CONSORT 2010 State‑
ment thus addresses the minimum criteria, although that 
should not deter authors from including other information 
if they consider it important.
After the meeting, the CONSORT Executive convened 
teleconferences and meetings to revise the checklist. After 
seven major iterations, a revised checklist was distributed to 
the larger group for feedback. With that feedback, the execu‑
tive met twice in person to consider all the comments and to 
produce a penultimate version. That served as the basis for 
writing the first draft of this paper, which was then distrib‑
uted to the group for feedback. After consideration of their 
comments, the executive finalised the statement.
The CONSORT Executive then drafted an updated expla‑
nation and elaboration manuscript, with assistance from 
other members of the larger group. The substance of the 2007 
CONSORT meeting provided the material for the update. The 
updated explanation and elaboration manuscript was distrib‑
uted to the entire group for additions, deletions, and changes. 
That final iterative process converged to the CONSORT 2010 
Explanation and Elaboration.13
changes in consort 2010
The revision process resulted in evolutionary, not revolution‑
ary, changes to the checklist (table), and the flow diagram 
was not modified except for one word (figure). Moreover, 
because other reporting guidelines augmenting the check‑
list refer to item numbers, we kept the existing items under 
their previous item numbers except for some renumbering of 
items 2 to 5. We added additional items either as a sub‑item 
under an existing item, an entirely new item number at the 
end of the checklist, or (with item 3) an interjected item into 
a renumbered segment. We have summarised the noteworthy 
general changes in box 1 and specific changes in box 2. The 
CONSORT website contains a side by side comparison of the 
2001 and 2010 versions.
implications and limitations
We developed CONSORT 2010 to assist authors in writing 
reports of randomised controlled trials, editors and peer 
reviewers in reviewing manuscripts for publication, and read‑
ers in critically appraising published articles. The CONSORT 
2010 Explanation and Elaboration provides elucidation 
and context to the checklist items. We strongly recommend 
using the explanation and elaboration in conjunction with 
the checklist to foster complete, clear, and transparent report‑
ing and aid appraisal of published trial reports.
CONSORT 2010 focuses predominantly on the two group, 
parallel randomised controlled trial, which accounts for 
over half of trials in the literature.2 Most of the items from 
the CONSORT 2010 Statement, however, pertain to all types 
of randomised trials. Nevertheless, some types of trials or 
trial situations dictate the need for additional information 
in the trial report. When in doubt, authors, editors, and read‑
ers should consult the CONSORT website for any CONSORT 
extensions, expansions (amplifications), implementations, 
or other guidance that may be relevant.
The evidence based approach we have used for CONSORT 
also served as a model for development of other reporting 
guidelines, such as for reporting systematic reviews and 
meta‑analyses of studies evaluating interventions,16 diag‑
nostic studies,17 and observational studies.18 The explicit 
goal of all these initiatives is to improve reporting. The 
Enhancing the Quality and Transparency of Health Research 
(EQUATOR) Network will facilitate development of report‑
ing guidelines and help disseminate the guidelines: www.
equator‑network.org provides information on all reporting 
guidelines in health research.
With CONSORT 2010, we again intentionally declined to 
produce a rigid structure for the reporting of randomised tri‑
als. Indeed, SORT19 tried a rigid format, and it failed in a pilot 
run with an editor and authors.20 Consequently, the format 
of articles should abide by journal style, editorial directions, 
the traditions of the research field addressed, and, where pos‑
sible, author preferences. We do not wish to standardise the 
structure of reporting. Authors should simply address check‑
list items somewhere in the article, with ample detail and 
lucidity. That stated, we think that manuscripts benefit from 
frequent subheadings within the major sections, especially 
the methods and results sections.
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Box 2 | Noteworthy specific changes in CONSORT 2010 Statement
•	Item 1b (title and abstract)—We added a sub-item on providing a structured summary of trial design, methods, results, and conclusions and referenced the CONSORT 
for abstracts article21
•	Item 2b (introduction)—We added a new sub-item (formerly item 5 in CONSORT 2001) on “Specific objectives or hypotheses”
•	Item 3a (trial design)—We added a new item including this sub-item to clarify the basic trial design (such as parallel group, crossover, cluster) and the allocation ratio
•	Item 3b (trial design)—We added a new sub-item that addresses any important changes to methods after trial commencement, with a discussion of reasons
•	Item 4 (participants)—Formerly item 3 in CONSORT 2001
•	Item 5 (interventions)—Formerly item 4 in CONSORT 2001. We encouraged greater specificity by stating that descriptions of interventions should include “sufficient 
details to allow replication”3
•	Item 6 (outcomes)—We added a sub-item on identifying any changes to the primary and secondary outcome (endpoint) measures after the trial started. This followed 
from empirical evidence that authors frequently provide analyses of outcomes in their published papers that were not the prespecified primary and secondary 
outcomes in their protocols, while ignoring their prespecified outcomes (that is, selective outcome reporting).4 22 We eliminated text on any methods used to enhance 
the quality of measurements
•	Item 9 (allocation concealment mechanism)—We reworded this to include mechanism in both the report topic and the descriptor to reinforce that authors should 
report the actual steps taken to ensure allocation concealment rather than simply report imprecise, perhaps banal, assurances of concealment
•	Item 11 (blinding)—We added the specification of how blinding was done and, if relevant, a description of the similarity of interventions and procedures. We also 
eliminated text on “how the success of blinding (masking) was assessed” because of a lack of empirical evidence supporting the practice as well as theoretical 
concerns about the validity of any such assessment23 24
•	Item 12a (statistical methods)—We added that statistical methods should also be provided for analysis of secondary outcomes
•	Sub-item 14b (recruitment)—Based on empirical research, we added a sub-item on “Why the trial ended or was stopped”25
•	Item 15 (baseline data)—We specified “A table” to clarify that baseline and clinical characteristics of each group are most clearly expressed in a table
•	Item 16 (numbers analysed)—We replaced mention of “intention to treat” analysis, a widely misused term, by a more explicit request for information about retaining 
participants in their original assigned groups26
•	Sub-item 17b (outcomes and estimation)—For appropriate clinical interpretability, prevailing experience suggested the addition of “For binary outcomes, 
presentation of both relative and absolute effect sizes is recommended”27
•	Item 19 (harms)—We included a reference to the CONSORT paper on harms28
•	Item 20 (limitations)—We changed the topic from “Interpretation” and supplanted the prior text with a sentence focusing on the reporting of sources of potential bias 
and imprecision
•	Item 22 (interpretation)—We changed the topic from “Overall evidence.” Indeed, we understand that authors should be allowed leeway for interpretation under 
this nebulous heading. However, the CONSORT Group expressed concerns that conclusions in papers frequently misrepresented the actual analytical results and 
that harms were ignored or marginalised. Therefore, we changed the checklist item to include the concepts of results matching interpretations and of benefits being 
balanced with harms
•	Item 23 (registration)—We added a new item on trial registration. Empirical evidence supports the need for trial registration, and recent requirements by journal 
editors have fostered compliance29
•	Item 24 (protocol)—We added a new item on availability of the trial protocol. Empirical evidence suggests that authors often ignore, in the conduct and reporting of 
their trial, what they stated in the protocol.4 22 Hence, availability of the protocol can instigate adherence to the protocol before publication and facilitate assessment 
of adherence after publication
•	Item 25 (funding)—We added a new item on funding. Empirical evidence points toward funding source sometimes being associated with estimated treatment effects30
CONSORT urges completeness, clarity, and transparency 
of reporting, which simply reflects the actual trial design 
and conduct. However, as a potential drawback, a reporting 
guideline might encourage some authors to report fictitiously 
the information suggested by the guidance rather than what 
was actually done. Authors, peer reviewers, and editors 
should vigilantly guard against that potential drawback and 
refer, for example, to trial protocols, to information on trial 
registers, and to regulatory agency websites. Moreover, the 
CONSORT 2010 Statement does not include recommenda‑
tions for designing and conducting randomised trials. The 
items should elicit clear pronouncements of how and what 
the authors did, but do not contain any judgments on how 
and what the authors should have done. Thus, CONSORT 
2010 is not intended as an instrument to evaluate the quality 
of a trial. Nor is it appropriate to use the checklist to construct 
a “quality score.”
Nevertheless, we suggest that researchers begin trials with 
their end publication in mind. Poor reporting allows authors, 
intentionally or inadvertently, to escape scrutiny of any weak 
aspects of their trials. However, with wide adoption of CON‑
SORT by journals and editorial groups, most authors should 
have to report transparently all important aspects of their 
trial. The ensuing scrutiny rewards well conducted trials and 
penalises poorly conducted trials. Thus, investigators should 
understand the CONSORT 2010 reporting guidelines before 
starting a trial as a further incentive to design and conduct 
their trials according to rigorous standards.
CONSORT 2010 supplants the prior version published in 
2001. Any support for the earlier version accumulated from 
journals or editorial groups will automatically extend to this 
newer version, unless specifically requested otherwise. Jour‑
nals that do not currently support CONSORT may do so by 
registering on the CONSORT website. If a journal supports or 
endorses CONSORT 2010, it should cite one of the original 
versions of CONSORT 2010, the CONSORT 2010 Explanation 
and Elaboration, and the CONSORT website in their “Instruc‑
tions to authors.” We suggest that authors who wish to cite 
CONSORT should cite this or another of the original journal 
versions of CONSORT 2010 Statement, and, if appropriate, 
the CONSORT 2010 Explanation and Elaboration.13 All CON‑
SORT material can be accessed through the original publish‑
ing journals or the CONSORT website. Groups or individuals 
who desire to translate the CONSORT 2010 Statement into 
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other languages should first consult the CONSORT policy 
statement on the website.
We emphasise that CONSORT 2010 represents an evolving 
guideline. It requires perpetual reappraisal and, if necessary, 
modifications. In the future we will further revise the CON‑
SORT material considering comments, criticisms, experi‑
ences, and accumulating new evidence. We invite readers to 
submit recommendations via the CONSORT website.
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